GlassScriptPhysician profile
Elias V Belezos
NPI 1205819109
$937.57
in general payments reported to CMS, 2019-2025
16 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $784 · 2020: $138 · 2022: $15.91.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astellas Pharma US INC | $140.42 | 2019-2020 | |
| Glaxosmithkline, LLC. | $140.09 | 2019 | |
| Lilly USA, LLC | $123.84 | 2019 | |
| Astrazeneca Pharmaceuticals LP | $103.60 | 2019-2020 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $82.56 | 2019 | |
| Janssen Pharmaceuticals, INC | $70.68 | 2019-2020 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $70.48 | 2019 | |
| Pfizer INC. | $62.39 | 2019-2020 | |
| Scilex Pharmaceuticals INC. | $33.74 | 2019 | |
| Amarin Pharma, INC. | $19.09 | 2020 | |
| Amgen INC. | $18.18 | 2019 | |
| Novo Nordisk INC | $17.18 | 2019 | |
| Abbott Laboratories | $15.91 | 2022 | |
| Merck Sharp & Dohme LLC | $14.98 | 2019 | |
| Novartis Pharmaceuticals Corporation | $13.63 | 2019 |
Show all 16 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| E.R. Squibb & Sons, L.L.C. | $10.80 | 2019 |
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Elias Belezos listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.